Extrafoveal vitreous traction associated with diabetic diffuse macular oedema

Eye

Volumn 24, Issue 2, 2010, Pages 347-353

  Ophir, A ^a,b   Trevino, A ^a   Fatum, S ^a  

^a HILLEL YAFFE MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Diabetic macular oedema; Diffuse macular oedema; Extrafoveal vitreous traction; Optical coherence tomography; Vitreofoveal traction; Vitreopapillary traction

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC DIFFUSE MACULAR EDEMA; DIABETIC PATIENT; DISEASE ASSOCIATION; EQUIPMENT; EXTRAFOVEAL VITREOUS TRACTION; EYE; FEMALE; HUMAN; MALE; MEDICAL RECORD REVIEW; OPTIC NERVE; OPTICAL COHERENCE TOMOGRAPHY; RETINA FOVEA; RETINA MACULA EDEMA; RETINA MACULA LUTEA; RETROSPECTIVE STUDY; VITREOUS BODY; VITREOUS DISEASE;

EID: 77049084070     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2009.106     Document Type: Article

References (32)

1. Cunha-Vaz JG. The blood-retinal barriers. Doc Ophthalmol 1976; (15)41: 287-327.
2. Vinores SA, Youssri AI, Luna JD, Chen YS, Bhargave S, VinoresMA et al. Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol Histopathol 1997; 12: 99-109.
3. Lobo CL, Bernardes RC, de Abreu JR, Cunha-Vaz JG. One-year follow-up of blood-retinal barrier and retinal thickness alterations in patients with type 2 diabetes mellitus and mild nonproliferative retinopathy. Arch Ophthalmol 2001; 199: 1469-1474.
4. Sander B, Larsen M, Moldow B, Lund-Anderden H. Diabetic macular oedema: passive and active transport of fluorescein through the blood-retina barrier. Invest Ophthalmol Vis Sci 2001; 42: 433-438.
5. Oauml T, Xu O, Joussen AM, Clemens MW, Qin W, Miyamoto K et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 2001; 42: 2408-2413.
6. Early Treatment Diabetic Retinopathy Study Research Group. Early Treatment Diabetic Retinopathy Study report no 1: photocoagulation for diabetic macular oedema. Arch Ophthalmol 1985; 103: 1796-1806.
7. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular oedema: long term visual results. Ophthalmology 1991; 98: 1594-1602.
8. Jonas JB, Kreissig I, Sofker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular oedema. Arch Ophthalmol 2003; 121: 57-61.
9. Ohguro N, Okada AA, Tano Y. Trans-Tenon's retrobulbar traimcinolone infusion for diffuse diabetic macular oedema. Graefe's Arch Clin Exp Ophthalmol 2004; 242: 444-445.
10. Shinura M, Nakazawa T, Yasuda K, Shiono T, Iida T, Sakamoto T et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular oedema. Am J Ophthalmol 2008; 145: 854-861.
11. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular oedema. Retina 2006; 26: 999-1005.
12. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME et al. for the Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin R): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008; 246: 81-87.
13. Kaiser PK, Riemann CD, Sears JE, Lewis H. Macular traction detachment and diabetic macular oedema associated with posterior hyaloidal traction. Am J Ophthalmol 2001; 131: 44-49. (Pubitemid 32037007)
14. Dillinger P, Mester U. Vitrectomy with removal of the internal limiting membrane in chronic diabetic macular oedema. Graefe's Arch Clin Exp Ophthalmol 2004; 242: 630-637.
15. Shah SP, Patel M, Thomas D, Aldington S, Laidlaw DA. Factors predicting outcome of vitrectomy for diabetic macular oedema: results of a prospective study. Br J Ophthalmol 2006; 90: 33-36.
16. Karatas M, Ramirez JA, Ophir A. Diabetic vitreopapillary traction and macular oedema. Eye 2005; 19: 676-682.
17. Lewis H, Abrams GW, Blumenkrnaz MS, Campo RV. Vitrectomy for diabetic macular traction and oedema associated with posterior hyaloidal traction. Ophthalmology 1992; 99: 753-759.
18. Massin P, Duguid G, Erginay A, Haouchine B, Gaudric A. Optical coherence tomography for evaluating diabetic macular oedema before and after vitrectomy. Am J Ophthalmol 2003; 135: 169-177.
19. Song SJ, Sohn JH, Park KH. Evaluation of the efficacy of vitrectomy for persistent diabetic macular oedema and associated factors predicting outcome. Korean J Ophthalmol 2007; 21: 146-150.
20. Figueroa MS, Contreras I, Noval S. Surgical and anatomical outcomes of pars plana vitrectomy for diffuse nontractional diabetic macular oedema. Retina 2008; 28: 420-426.
21. La Heij EC, Hendrikse F, Kessels AG, Derhaag PJ. Vitrectomy results in diabetic macular oedema without evident vitreomacular traction. Graefe's Arch Clin Exp Ophthalmol 2001; 239: 264-270.
22. Hee MR. Artifacts in optical coherence tomography topographic maps. Am J Ophthalmol 2005; 139: 154-155.
23. GoebelW, Kretzchmar-Gross T. Retinal thickness in diabetic retinopathy: a study using optical coherence tomography (OCT). Retina 2002; 22: 759-767.
24. Massin P, Vicaut E, Haouchine B, Erginay A, Paques M, Gaudric A. Reproducibility of retinal mapping using optical coherence tomography. Arch. Ophthalmol. 2001; 119: 1135-1142.
25. Ramirez JA, Ophir A. Inner lamellar macular holes vs. macular pseudoholes with normal foveal thickness. Int J Ophthalmol (China) 2003; 3: 4-8.
26. Yanayali A, Horozoglu F, Celik E, Nohutcu AF. Long-term outcomes of pars plana vitrectomy with internal limiting membrane removal in diabetic macular oedema. Retina 2007; 27: 557-566.
27. Nguyen QD, Tatlipinar S, Shah SM, Haller JA, Quinlan E, Sung J et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular oedema. Am J Ophthalmol 2006; 142: 961-969.
28. Patel JI, Hykin PG, Schadt M, Loung V, Bunce C, Fitzke F et al. Diabetic macular oedema: pilot randomised trial of pars plana vitrectomy vs. macular argon photocoagulation. Eye 2006; 20: 873-881. (Pubitemid 44210178)
29. Arevalo JF, Maia M, Flynn Jr HW, Saravia M, Avery RL, Wu L et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008; 92: 213-216.
30. Honda S, Hirabayashi H, Tsukahara Y, Negi A. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2008; 246: 1061-1063.
31. Gallemore RP, Jumper JM, McCuen BW, Jaffe GJ, Postel EA, Toth CA. Diagnosis of vitreoretinal adhesions in macular disease with optical coherence tomography. Retina 2000; 20: 115-120.
32. Nassif N, Cense B, Park BH, Yun SH, Chen TC, Bouma BE et al. In vivo human retinal imaging by ultrahigh-speed spectral domain optical coherence tomography. Opt Lett 2004; 29: 480-482.